Table 1. Baseline characteristics of all patients and subgroups according to the levels of PD-1, PD-L1, and PD-L2 expression.
| Clinical features, n (%) | Entire cohort | Subgroups | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (n = 76) | PD-1 | P | PD-L1 | P | PD-L2 | P | ||||
| Low (n = 70) | High (n = 6) | Low (n = 66) | High (n = 10) | Low (n = 44) | High (n = 32) | |||||
| Median age, year | 57 (33-79) | 56 (33-79) | 59 (34-68) | 56 (33-79) | 59 (34-64) | 58 (36-79) | 56 (33-74) | |||
| Age >60 | 30 (39.5) | 28 (40.0) | 2 (33.3) | 0.556 | 28 (42.4) | 2 (20.0) | 0.158 | 27 (61.4) | 19 (59.4) | 0.524 |
| Male gender | 39 (51.3) | 36 (51.4) | 3 (50.0) | 0.637 | 35 (53.0) | 4 (40.0) | 0.334 | 23 (52.3) | 16 (50.0) | 0.514 |
| ECOG PS ≥2 | 35 (46.1) | 34 (48.6) | 1 (16.7) | 0.209 | 29 (43.9) | 6 (60.0) | 0.271 | 17 (38.6) | 18 (56.3) | 0.099 |
| Elevated serum LDH | 34 (44.7) | 33 (47.1) | 1 (16.7) | 0.216 | 29 (43.9) | 5 (50.0) | 0.489 | 20 (45.5) | 14 (43.8) | 0.535 |
| Deep lesion | 51 (67.1) | 47 (67.1) | 4 (66.7) | 0.649 | 43 (65.2) | 8 (80.0) | 0.293 | 27 (61.4) | 24 (75.0) | 0.158 |
| Elevated CSF protein | 30/66 (39.4) | 28/61 (40.0) | 2/5 (33.3) | 0.587 | 27/57 (40.9) | 3/9 (30.0) | 0.339 | 18/39 (40.9) | 12/27 (37.5) | 0.546 |
| Positive serum EBV | 16 (21.1) | 14 (20.0) | 2 (33.3) | 0.371 | 14 (21.2) | 2 (20.0) | 0.648 | 11 (25.0) | 5 (15.6) | 0.242 |
| Histology, DLBCL/PTCL | 75(98.7)/1(1.3) | 69(98.6)/1(1.4) | 6(100.0)/0(0.0) | 0.921 | 65(98.5)/1(1.5) | 10(100.0)/0(0.0) | 0.868 | 43(97.7)/1(2.3) | 32(100.0)/0(0.0) | 0.579 |
| IELSG | 0.257 | 0.507 | 0.097 | |||||||
| Low (0-1) | 12 (15.8) | 10 (14.3) | 2 (33.3) | 10 (15.2) | 2 (20.0) | 8 (18.2) | 4 (12.5) | |||
| Intermediate (2-3) | 46 (60.5) | 43 (61.4) | 3 (50.0) | 41 (62.1) | 5 (50.0) | 29 (65.9) | 17 (53.1) | |||
| High (4-5) | 8 (10.5) | 8 (11.4) | 0 (0.0) | 6 (9.1) | 2 (20.0) | 2 (4.5) | 6 (18.8) | |||
| Missing | 10 (13.2) | 9 (12.9) | 1 (16.7) | 9 (13.6) | 1 (10.0) | 5 (11.4) | 5 (15.6) | |||
| MSKCC | 0.180 | 0.433 | 0.208 | |||||||
| Low (0) | 15 (19.7) | 13 (18.6) | 2 (33.3) | 13 (19.7) | 2 (20.0) | 9 (20.5) | 6 (18.8) | |||
| Intermediate (1) | 32 (42.1) | 29 (41.4) | 3 (50.0) | 27 (40.9) | 5 (50.0) | 21 (47.7) | 11 (34.4) | |||
| High (2) | 29 (38.2) | 28 (40.0) | 1 (16.7) | 26 (39.4) | 3 (30.0) | 14 (31.8) | 15 (46.9) | |||
| Initial treatment MVD/MVP | 41(53.9)/35(46.1) | 37(52.9)/33(47.1) | 4(66.7)/2(33.3) | 0.416 | 40(60.6)/26(39.4) | 1(10.0)/9(90.0) | 0.003 | 25(56.8)/19(43.2) | 16(50.0)/16(50.0) | 0.361 |
| Non-CR1 | 37 (48.7) | 34 (48.6) | 3 (50.0) | 0.389 | 31 (47.0) | 6 (60.0) | 0.562 | 22 (50.0) | 15 (46.9) | 0.380 |
| Upfront ASCT | 16 (21.1) | 15 (21.4) | 1 (16.7) | 0.629 | 13 (19.7) | 3 (30.0) | 0.352 | 9 (20.5) | 7 (21.9) | 0.550 |
| Salvage ASCT | 10 (13.2) | 8 (11.4) | 2 (33.3) | 0.176 | 9 (13.6) | 1 (10.0) | 0.609 | 7 (15.9) | 3 (9.4) | 0.318 |
| Consolidation WBRT | 12 (15.8) | 8 (11.4) | 4 (66.7) | 0.657 | 5 (7.6) | 7 (70.0) | 0.495 | 7 (15.9) | 5 (15.6) | 0.384 |
| Salvage WBRT | 14 (18.4) | 13 (18.6) | 1 (16.7) | 0.696 | 12 (18.2) | 2 (20.0) | 0.590 | 9 (20.5) | 5 (15.6) | 0.411 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate dehydrogenase; CSF, cerebrospinal fluid; EBV, Epstein-Barr virus; DLBCL, diffuse large B-cell lymphoma; PTCL, peripheral T-cell lymphoma; IELSG, International Extranodal Lymphoma Study Group; MSKCC, Memorial Sloan Kettering Cancer Center; MVD, methotrexate, vincristine and dexamethasone; MVP, methotrexate, vincristine, procarbazine and dexamethasone; CR1, complete response after first two cycles of chemotherapy; ASCT, autologous stem-cell transplantation; WBRT, whole-brain radiotherapy.